Novel chorioretinal findings in two siblings with mucopolysaccharidosis type VI. (3rd September 2022)

• Record Type: Journal Article
• Authors: Kowalski, Tanya; Donoghue, Sarah; de Jong, Gerard; Mack, Heather G.
• Is Part Of: Ophthalmic genetics. Volume 43:Number 5(2022)
• Page Start: 693
• Page End: 698
• Publication Date: 2022-09-03
• Subjects: Mucopolysaccharidosis type VI -- Maroteaux–Lamy syndrome -- galsulfase -- choroid -- retina; Eye -- Diseases -- Genetic aspects -- Periodicals; Eye Diseases -- genetics -- Periodicals; Eye Diseases -- in infancy & childhood -- Periodicals; 617.7
• DOI: 10.1080/13816810.2022.2083184
• Languages: English
• ISSNs: 1381-6810

Abstract

ABSTRACT: Purpose: To describe and compare the systemic and ocular findings in two siblings with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome), one treated with recombinant galsulfase, and one who was untreated. Method: One female patient aged 33 years (case 1) who had received galsulfase enzyme replacement therapy for 11 years, and her younger male sibling by 3 years (case 2), who had declined systemic treatment, underwent clinical ophthalmic examination and retinal ocular coherence tomography. The female sibling underwent electrophysiology testing of visual function. Results: Case 1 had best corrected visual acuity right 6/4.8 and left 6/6. Case 2 had best corrected visual acuity of 6/6 in each eye. Case 1 had bilateral mild corneal haze and a clinically unremarkable posterior segment examination. Case 2 had bilateral very mild corneal haze and retinal striae on examination. Ocular coherence tomography showed choroidal folds at the maculae in both patients, more pronounced in Case 2, who also had retinal folds and epiretinal membrane. Electroretinography showed very mild involvement of the rods only in Case 1. Conclusion: These two siblings with mucopolysaccharidosis type VI, one treated and one untreated, displayed variable levels of systemic, corneal, and chorioretinal involvement in their disease Further studies of choroidal changes in MPS VI may prove useful as a biomarker of ocular response to treatment outside the blood-retina barrier. Both patients have provided written consent to publish case details.